A case of disseminated cryptococcal disease after Bruton tyrosine kinase inhibitor therapy: A brief review in the Australian context

Loading...
Thumbnail Image
File version

Version of Record (VoR)

Author(s)
Van Rooij, N
Johnston, J
Mortimore, R
Robertson, I
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2021
Size
File type(s)
Location
Abstract

The use of Bruton tyrosine kinase (BTK) inhibitors for the treatment of a number of hematological conditions is rapidly increasing. Ibrutinib is the most clinically advanced and common BTK inhibitor currently utilized. Its use, however, comes with increasing reports of immunosuppression and increased risk of opportunistic infections.1 We present the case of a widespread papulonodular eruption secondary to disseminated cryptococcal disease after ibrutinib therapy, which the authors believe is the first reported case with widespread cutaneous involvement.

Journal Title

JAAD Case Reports

Conference Title
Book Title
Edition
Volume

13

Issue
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement

© 2021 Published by Elsevier on behalf of the American Academyof Dermatology, Inc. This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.

Item Access Status
Note
Access the data
Related item(s)
Subject

Clinical sciences

BTK, Bruton tyrosine kinase

dermatology

drug reaction

eruption

hematology

Persistent link to this record
Citation

Van Rooij, N; Johnston, J; Mortimore, R; Robertson, I, A case of disseminated cryptococcal disease after Bruton tyrosine kinase inhibitor therapy: A brief review in the Australian context, JAAD Case Reports, 2021, 13, pp. 43-45

Collections